HBIO is the ticker symbol for HARVARD BIOSCIENCE INC, a publicly traded Technology sector company listed on Nasdaq. 13F Pro tracks HBIO with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is HBIO a good stock to buy?

13F Pro's AI ranking engine scores HBIO at 26.5/100, ranked #2,621 of 2,962 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for HBIO is available at https://13fpro.ai/company/HBIO. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source HBIO data?

All HARVARD BIOSCIENCE INC fundamentals and ownership data come directly from SEC EDGAR. HARVARD BIOSCIENCE INC files with the SEC under CIK 1123494. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

HARVARD BIOSCIENCE INC(HBIO)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

HARVARD BIOSCIENCE INC (HBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores HBIO at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,621 of 2,962 stocks — the bottom half of the AI-ranked universe. HBIO scores in the top quartile across institutional flow (99.4). Areas of concern include revenue growth (10.5) and revenue scale (13.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HARVARD BIOSCIENCE INC reports quarterly revenue of $22.7M, net income of $-2.9M, an operating margin of -4.3%. Top institutional holders of HBIO by reported 13-F value include WEBER CAPITAL MANAGEMENT, Meros Investment Management, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. HBIO trades on the Nasdaq exchange and files with the SEC under CIK 1123494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARVARD BIOSCIENCE INC directly from SEC EDGAR.

AI Quality Score

26.5/100

AI Rank

#2,621

Revenue

$22.7M

Net Income

$-2.9M

Free Cash Flow

$-363.0K

Operating Margin

-4.3%

HBIO key financials by period

HARVARD BIOSCIENCE INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$86.5M	$-56.7M	-56.1%
FY 2024	10-K	$94.1M	$-12.4M	-6.6%
FY 2023	10-K	$112.3M	$-3.4M	1.7%
FY 2022	10-K	$113.3M	$-9.5M	-6.1%
FY 2021	10-K	$118.9M	$-288.0K	1.7%
FY 2020	10-K/A	$102.1M	$-7.8M	0.2%

Institutions holding HBIO

Institutional investors reporting a position in HARVARD BIOSCIENCE INC on SEC Form 13F.
Institution	Shares	Value	Reported
WEBER CAPITAL MANAGEMENT	310,861	$1.9M	2026-06-30
Meros Investment Management	182,992	$1.1M	2026-06-30
ACADIAN ASSET MANAGEMENT	179,614	$1.1M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	169,625	$1.0M	2026-06-30
NANO CAP NEW MILLENNIUM GROWTH FUND L P	143,082	$880.0K	2026-06-30
CORSAIR CAPITAL MANAGEMENT, L.P.	122,810	$755.3K	2026-06-30
TWO SIGMA INVESTMENTS	114,545	$704.5K	2026-06-30
RENAISSANCE TECHNOLOGIES	99,327	$610.9K	2026-06-30
BlackRock	61,834	$380.3K	2026-06-30
GEODE CAPITAL MANAGEMENT	47,555	$292.5K	2026-06-30